BRIEF—WuXi AppTec acquires Pharmapace

China’s WuXi AppTec has acquired Pharmapace, a USA-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support.

Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the newly-rebranded and enlarged clinical contract research organization (CRO) arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.

The enlarged CRO has more than 850 employees located in China and the USA, together with its close partners in Europe, Asia Pacific. The company says it can provide customers full services clinical development services as well as functional service provider worldwide.

Jonathan Lee, general manager and head of WuXi Clinical, called it a "hugely exciting time for WuXi Clinical."